Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect function of stem cell derived cardiomyocytes, 2024, Sinclair+

Discussion in 'Long Covid research' started by SNT Gatchaman, Apr 13, 2024.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    Now published: link here

    Preprint
    Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect the function of human pluripotent stem cell derived cardiomyocytes

    Jane Sinclair; Courtney Vedelago; Feargal Ryan; Meagan Carney; Meredith Redd; Miriam Lynn; Branka Grubor-Bauk; Yuanzhao Cao; Anjali Henders; Keng Yih Chew; Deborah Gilroy; Kim Greaves; Larisa Labzin; Laura Ziser; Katharina Ronacher; Leanne Wallace; Yiwen Zhang; Kyle Macauslane; Daniel Ellis; Sudha Rao; Lucy Burr; Amanda Bain; Benjamin L. Schulz; Junrong Li; David J. Lynn; Nathan Palpant; Alain Wuethrich; Matt Trau; Kirsty Short

    Globally, over 65 million individuals are estimated to suffer from post-acute sequelae of COVID-19 (PASC). A large number of individuals living with PASC experience cardiovascular symptoms (i.e. chest pain and heart palpitations) (PASC-CVS). The role of chronic inflammation in these symptoms, in particular in individuals with symptoms persisting for >1 year after SARS-CoV-2 infection, remains to be clearly defined.

    In this cross-sectional study, blood samples were obtained from three different sites in Australia from individuals with i) a resolved SARS-CoV-2 infection (and no persistent symptoms i.e. Recovered), ii) individuals with prolonged PASC-CVS and iii) SARS-CoV-2 negative individuals.

    Individuals with PASC-CVS, relative to Recovered individuals, had a blood transcriptomic signature associated with inflammation. This was accompanied by elevated levels of pro-inflammatory cytokines (IL-12, IL-1beta;, MCP-1 and IL-6) at approximately 18 months post-infection. These cytokines were present in trace amounts, such that they could only be detected with the use of novel nanotechnology. Importantly, these trace-level cytokines had a direct effect on the functionality of pluripotent stem cell derived cardiomyocytes in vitro. This effect was not observed in the presence of dexamethasone. Plasma proteomics demonstrated further differences between PASC-CVS and Recovered patients at approximately 18 months post-infection including enrichment of complement and coagulation associated proteins in those with prolonged cardiovascular symptoms.

    Together, these data provide a new insight into the role of chronic inflammation in PASC-CVS and present nanotechnology as a possible novel diagnostic approach for the condition.


    Link | PDF (Preprint: BioRxiv) [Open Access]
     
    Last edited by a moderator: Oct 31, 2024
    Mij, Hutan, John Mac and 2 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,697
    Location:
    Aotearoa New Zealand
    RNA sequencing for gene expression
    25 PASC (persistent symptoms)
    11 Recovered
    14 healthy controls negative for SARS-CoV-2 spike protein (HC)
    (note that these are already rather small numbers)

    So people with a history of Covid-19 looked different to healthy controls.
    Figure 1A is blurred in this preprint, but it is clear that PASC and Recovered are not separated in the Principal Component Analysis.

    At 44 weeks after infection, PASC had more than 400 differentially expressed genes while Recovered had less than 200 differentially expressed genes, compared to healthy controls.
    At 68 weeks after infection, both PASC and Recovered had around 200 differentially expressed genes.

    Gene set enrichment analysis - to identify affected pathways
    Comparing HCs and any individuals who had had Covid-19:
    Comparing PASC and Recovered:
    PASC-CVS (PASC with cardiovascular symptoms) - compared with Recovered
    To reiterate - there were only 4 individuals at each timepoint with PASC-CVS. It's not clear to me yet whether they were even the same 4 individuals at each timepoints. So, it seems a bit of an odd focus of the paper and rings alarm bells for cherry-picking.
     
    Last edited: Apr 13, 2024
    Lou B Lou and SNT Gatchaman like this.
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,697
    Location:
    Aotearoa New Zealand
    But wait - there's more!
    More PASC-CVS compared with Recovered
    They found an independent cohort of 5 PASC-CVS and 4 Recovered at >520 days post-infection. So, again, very small numbers. It sounds as though similar pathways were identified as in the first PASC-CVS versus Recovered analysis, but it's a bit vague.

    Figure 2 does look quite convincing, but, you know, ...5 PASC-CVS and 4 Recovered. Are we just seeing the difference between people with and without heart disease? Do the PASC-CVS actually have much to do with PASC with fatigue?

    Screen Shot 2024-04-14 at 2.57.28 am.png
    Screen Shot 2024-04-14 at 3.00.41 am.png

    And there's still more, but taking a break.
     
    SNT Gatchaman and alktipping like this.
  4. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    Now published as —

    Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function
    Sinclair, Jane E.; Vedelago, Courtney; Ryan, Feargal J.; Carney, Meagan; Redd, Meredith A.; Lynn, Miriam A.; Grubor-Bauk, Branka; Cao, Yuanzhao; Henders, Anjali K.; Chew, Keng Yih; Gilroy, Deborah; Greaves, Kim; Labzin, Larisa; Ziser, Laura; Ronacher, Katharina; Wallace, Leanne M.; Zhang, Yiwen; Macauslane, Kyle; Ellis, Daniel J.; Rao, Sudha; Burr, Lucy; Bain, Amanda; Karawita, Anjana; Schulz, Benjamin L.; Li, Junrong; Lynn, David J.; Palpant, Nathan; Wuethrich, Alain; Trau, Matt; Short, Kirsty R.

    An estimated 65 million people globally suffer from post-acute sequelae of COVID-19 (PASC), with many experiencing cardiovascular symptoms (PASC-CVS) like chest pain and heart palpitations.

    This study examines the role of chronic inflammation in PASC-CVS, particularly in individuals with symptoms persisting over a year after infection. Blood samples from three groups—recovered individuals, those with prolonged PASC-CVS and SARS-CoV-2-negative individuals—revealed that those with PASC-CVS had a blood signature linked to inflammation.

    Trace-level pro-inflammatory cytokines were detected in the plasma from donors with PASC-CVS 18 months post infection using nanotechnology. Importantly, these trace-level cytokines affected the function of primary human cardiomyocytes. Plasma proteomics also demonstrated higher levels of complement and coagulation proteins in the plasma from patients with PASC-CVS. This study highlights chronic inflammation’s role in the symptoms of PASC-CVS.

    Link | PDF (Nature Microbiology) [Open Access]
     
  5. Dolphin

    Dolphin Senior Member (Voting Rights)

    Messages:
    5,884

Share This Page